

SNMMI CLINICAL TRIALS NETWORK

Committee Report
SNMMI Board of Directors
January 2016

Highlights:

- The Clinical Trials Network (CTN) continues to work on **7 different investigational agents** being used in trials or in drug development projects. These include FLT, DOTATATE, DOTATOC, FDHT, F-Choline, Fluciclovine, and HX-4.
- CTN Gallium Users Group is now working on two prostate cancer protocols using ⁶⁸Ga-PSMA. The protocols have been reviewed and approved by FDA.
- CTN, in conjunction with the NCI, will host an **Imaging in Immunotherapy Think Tank** meeting. Tony Shields is the lead for NCI. The meeting will be held at NCI during the last week or April or first week of May.

Current projects of the CTN include:

- The CTN database is undergoing a complete data refresh. Imaging sites have been updated and the radiopharmaceutical manufacturing sites are under way now. Additionally, new sites outside of the US are being added, especially manufacturing sites. This information is being used by the Global Initiative.
- CTN continues to provide support for the 5-year NIH R01 grant on harmonizing PET reconstructions for cancer clinical trials. Staff assists academic centers with phantom scanning, oversees image upload and management in the Keosys Imagys server and provides general administrative report. Investigators will submit for the grant's fourth year of funding.
- Members of the SPECT Committee have developed a prototype SPECT phantom; testing should begin soon. A list of SOPs for the Committee was drafted, with priority assigned to personnel training and image review.

Fundraising:

CTN will hold a CTN Summit with pharmaceutical, equipment, and radiopharmaceutical manufacturing companies to update them on the programs that have been developed by CTN and how we can work together. The meeting will be scheduled for February 22, 2016. CTN will continue to investigate and apply for foundation and grant funding for general program support. CTN has recently developed ads to market the scanner validation program and to market the services of the CTN to academic investigators.

CTN continues to investigate ways to collaborate with other groups and industry partners on projects that benefit the entire molecular imaging community. CTN has been asked by the NCI Imaging Program, namely Paula Jacobs, to build a tool for connecting IND holders of PET drugs with potential would-be investigators. This site would eventually house INDs and other regulatory documents for ease of sharing and collaboration.

